Description

SEBI issued a confirmatory order against Par Drugs and Chemicals Limited (PDCL) for alleged fraudulent slump sale of core business to a promoter-related entity at undervalued consideration, violating SEBI Act, PFUTP Regulations, and LODR Regulations.

Summary

SEBI’s Whole Time Member issued a confirmatory order (WTM/KV/CFID/CFID-SEC4/32246/2025-26) against Par Drugs and Chemicals Limited (PDCL), a company listed on the National Stock Exchange (NSE), confirming the findings of an earlier ex-parte interim order dated September 15, 2025. PDCL was found to have allegedly engaged in a fraudulent slump sale of its core business operations to Phal-Jig Fine Chemicals Private Limited (PJFCPL), a promoter-related entity, at an erroneous and undervalued consideration, in violation of the SEBI Act, PFUTP Regulations, and LODR Regulations.

Key Points

  • PDCL is engaged in development and manufacturing of active pharma ingredients, antacid raw materials, and fine chemicals, listed on NSE with registered office in Vadodara, Gujarat.
  • SEBI received a complaint alleging the proposed slump sale of PDCL’s core profit-making business to PJFCPL (a promoter-related entity) was non-compliant and prejudicial to public shareholders.
  • The proposed transaction allegedly resulted in approximately 70% erosion of PDCL’s share value from the time the decision was made public.
  • PDCL announced the outcome of its board meeting approving the slump sale on December 02, 2024, and issued an EGM notice on December 06, 2024, scheduling the EGM for December 31, 2024.
  • SEBI passed an ex-parte interim order on September 15, 2025 for alleged contravention of the SEBI Act, PFUTP Regulations, and LODR Regulations.
  • The confirmatory order was passed under Sub-section (1) and (4) of Section 11, Section 11B, and Section 11D of the SEBI Act, 1992.
  • PDCL’s reply to the interim order and personal hearing were considered before confirming the order.

Regulatory Changes

No new regulatory changes introduced. The order applies existing provisions:

  • Securities and Exchange Board of India Act, 1992 — Sections 11(1), 11(4), 11B, and 11D
  • SEBI (Prohibition of Fraudulent and Unfair Trade Practices Relating to Securities Market) Regulations, 2003 (PFUTP Regulations)
  • SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations) — specifically Paragraph A of Part A of Schedule III regarding disclosure of slump sale details

Compliance Requirements

  • PDCL is subject to the directions imposed under the confirmatory order, which typically include restraints on accessing securities markets and on dealing in securities.
  • Listed companies must ensure that related-party transactions such as slump sales are disclosed accurately, completely, and at fair valuations as required under LODR Regulations Schedule III.
  • Promoters and management of listed companies must not engage in transactions that are prejudicial to public shareholders or constitute fraud under PFUTP Regulations.
  • Companies must provide adequate and timely information to shareholders before seeking approval for material transactions such as slump sales via EGM.

Important Dates

  • December 02, 2024: PDCL board meeting announcement regarding proposed slump sale.
  • December 06, 2024: EGM notice issued by PDCL.
  • December 31, 2024: EGM scheduled for shareholder approval of slump sale.
  • September 15, 2025: Ex-parte interim order passed by SEBI against PDCL.
  • March 25, 2026: Confirmatory order passed by SEBI’s Whole Time Member.

Impact Assessment

Investor Impact (High): Public shareholders of PDCL suffered approximately 70% erosion in share value as a result of the announced slump sale to a promoter-related entity. The confirmatory order signals SEBI’s intent to protect minority shareholders from fraudulent related-party asset transfers.

Market Impact (Medium): The order reinforces regulatory scrutiny over promoter-driven asset sales in listed companies, particularly where valuation is contested and public shareholders bear disproportionate harm.

Compliance Impact (High): Companies planning material transactions such as slump sales must ensure rigorous adherence to LODR disclosure norms and fair valuation standards. SEBI’s action signals heightened enforcement against transactions that erode minority shareholder value for promoter benefit.

Enforcement Signal: The use of Sections 11, 11B, and 11D collectively indicates SEBI’s use of its full enforcement toolkit — including directions, prohibitions, and disgorgement powers — to address fraudulent conduct in the securities market.

Impact Justification

SEBI confirmed interim order findings of fraudulent conduct by PDCL management — selling core business to a promoter entity at suppressed valuation, causing ~70% erosion in share value and harming public shareholders. Invokes multiple enforcement provisions including Section 11, 11B, and 11D of the SEBI Act.